[Cabergoline in hyperprolactinemia and valvular heart disease].
BACKGROUND
High-dose cabergoline therapy has been related to cardiac valve regurgitation in patients with Parkinson's disease.


OBJECTIVE
To perform a systematic analysis of reports on low-dose cabergoline treatment in hyperprolactinemia and its effect on the cardiac valves.


RESULTS
None of the seven reports analyzed, including 463 patients in total, found clinically significant valve regurgitation. Only one report found moderate tricuspid valve regurgitation, and other two reports found mild tricuspid valve regurgitation. An increase in the mitral tenting area was documented in only one of two reports. Valve thickening and calcifications were found in only one study.


CONCLUSIONS
Cabergoline seems to be safe at the doses employed in hyperprolactinemic patients. There is a higher prevalence of tricuspid regurgitation, detected by systematic echocardiography, but this abnormality is asymptomatic. Although prospective longitudinal studies are needed, vigilance of these patients is recommended, especially those treated with high-dose cabergoline.
Vargas
Marcos Lahera
ML
Servicio de Endocrinología y Nutrición, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, España. marcos.lahera@salud.madrid.org
Cervantes
Carlos Escobar
CE
Hernando
Carmen Alameda
CA
Da Costa
César Varela
CV
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism; D015995:Prevalence; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy / Q000378:metabolism; D014463:Ultrasonography
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline